查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030230

下一代生物療法市場－全球產業規模、佔有率、趨勢、機會和預測：按治療領域、技術、地區和競爭格局分類，2021-2031年

Next Generation Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球下一代生物製藥市場預計將從 2025 年的 57.1 億美元成長到 2031 年的 116.5 億美元，複合年成長率為 12.62%。

這些先進治療方法是基於複雜的生物系統和生物來源的分子，涵蓋基因療法、細胞療法、單株抗體療法和寡核苷酸療法。它們旨在為遺傳性疾病、癌症和自體免疫疾病等疾病提供高度標靶的治療。該領域的發展主要得益於全球罕見疾病和慢性病發病率的上升，這些疾病需要新的醫療解決方案，以及生物製藥研發領域的技術突破和資金籌措的增加。

市場概覽
預測期 2027-2031
市場規模：2025年 57.1億美元
市場規模：2031年 116.5億美元
複合年成長率：2026-2031年 12.62%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

然而，研發、生產和分銷這些複雜生物療法所需的高昂成本正嚴重阻礙市場的持續成長。根據美國製藥商協會（PhRMA）的數據，2025年核准的52種新藥中，僅有6種是新型疫苗和生物製藥。此外，生技創新組織（BIO）指出，生技新創公司的融資額從2025年第一季的26億美元驟降至第二季的9億美元，凸顯了該產業目前面臨的嚴峻財務挑戰。

市場促進因素

治療技術和生物技術的進步正在從根本上改變下一代生物製藥產業，促進了高度複雜的醫療干預措施的發展。基於RNA的治療方法、細胞療法和基因編輯的突破性進展，不僅引入了創新的作用機制，還擴大了可治療疾病的範圍。因此，先進生物製藥組合不斷豐富，並順利通過了監管核准流程。正如Contract Pharma於2026年3月2日發布的報告《2026年生物製劑浪潮：哪些創新將推動突破？ 》所述，截至2025年底，美國食品藥物管理局（FDA）藥物評估與研究中心（CDER）已核准了46種新藥治療方法，其中12種為生物製劑。這一趨勢凸顯了下一代生物療法的可行性和進展，進而吸引了更多資金和專業人才進入該領域。

全球市場另一個關鍵促進因素是對個人化、高度標靶醫療療法的需求日益成長，這標誌著醫療保健正朝著為每位患者量身定做的方向發生重大轉變。這種需求的激增源於人們對疾病多樣性的更深入了解，以及這些先進療法能夠比傳統療法帶來更好的療效和更少的副作用。這些個人化策略在罕見疾病和腫瘤等具有挑戰性的醫學領域尤其重要。 MarketWatch 於 2026 年 3 月 27 日發布的報告《2026-2033 年個人化醫療市場佔有率與機會》預測，到 2026 年，北美將佔據個人化醫療領域 44.4% 的佔有率，顯示該地區滲透率顯著。此外，大量投資正湧入整個生物製藥產業。根據 Fierce Biotech 發布的 2026 年報告，大型製藥企業僅在 2025 年 10 月和 11 月的兩個月內就斥資超過 360 億美元收購生技公司。這為向全球提供這些尖端治療方法所需的創新和基礎設施提供了保障。

市場挑戰

新一代生物製藥的研發、生產和分銷需要巨額資金，這是市場成長的主要障礙。這些先進治療方法需要嚴謹的科學研究、專門設計的生產設施以及嚴格的監管合規，導致整體成本極高。因此，這種經濟負擔可能導致最終療法的價格過高，限制更多患者獲得治療的機會，並最終阻礙其在市場上的廣泛接受和普及。

此外，推動這些治療方法所需的大量資本投入對新興生物技術新創公司和小型企業構成了重大障礙。籌集必要的資金以支持長期研究階段和大規模生產活動極具挑戰性，尤其是在投資者要求事先提供嚴格的概念驗證（PoC）的情況下。根據麻州生物技術委員會的數據，2025年，麻州企業的創業投資資金籌措達68.5億美元，共完成197輪投資。雖然這些數據顯示已恢復到疫情前的水平，但也凸顯了激烈的競爭環境，這可能會減緩突破性治療方法從實驗室走向商業市場的進程。

市場趨勢

將人工智慧 (AI) 引入新藥研發領域，正透過加速藥物發現過程和提高研發效率，顯著改變全球下一代生物製藥領域。這一趨勢超越了傳統的實驗室技術，利用先進的運算能力快速識別新的藥物標靶、設計更優的分子，並預測藥物的安全性和有效性。這些人工智慧應用正在革新藥物研發的早期階段，並促進一種更具適應性、數據驅動的方法。為了體現業界對這項技術進步的堅定信心，禮來公司和英偉達公司於 2026 年 1 月宣布，雙方將在未來五年內聯合投資高達 10 億美元，建立一個專注於新藥發現的人工智慧驅動型研究實驗室。

同時，社區型和臨床中心型生技藥品生產系統的興起也成為一大趨勢。這些系統在高效開發和供應針對罕見疾病和個人化醫療的尖端治療方法方面發揮著至關重要的作用。這種轉變利用位於病患和專科醫療機構附近的緊湊型、靈活型設施，避免了大規模集中式生產帶來的高成本和物流難題。此類模式採用連續生產等先進技術，從而減少了生技藥品生產通常所需的大量前期投資。正如MedCity News在2026年1月29日指出的那樣，使用連續生產技術可以將所需的設備空間減少高達70%，而且這些分散式生產網路具有顯著的成本效益和功能優勢。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球下一代生物療法市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療領域（腫瘤、自體免疫疾病和發炎性疾病）
    • 依技術分類（抗體藥物複合體、雙特異性抗體、抗體片段、抗體樣蛋白等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美下一代生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲下一代生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區下一代生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲下一代生物療法的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲下一代生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球下一代生物療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Xencor, Inc.
  • Regenxbio & Neurimmune AG
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Kirin Co., Ltd
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Ono Pharmaceuticals Co, Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 8069

The Global market for next-generation biotherapeutics is anticipated to expand from USD 5.71 billion in 2025 to USD 11.65 billion by 2031, reflecting a compound annual growth rate of 12.62%. These advanced treatments involve sophisticated biological systems and molecules sourced from living organisms, encompassing gene and cell therapies, monoclonal antibodies, and oligonucleotide therapeutics. They are formulated to provide highly targeted treatments for ailments such as genetic disorders, cancer, and autoimmune diseases. Growth in this sector is primarily fueled by the rising global incidence of rare and chronic illnesses that necessitate novel medical solutions, alongside major technological strides and boosted funding in biopharmaceutical research and development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.71 Billion
Market Size 2031USD 11.65 Billion
CAGR 2026-203112.62%
Fastest Growing SegmentOncology
Largest MarketNorth America

However, continuous market growth is significantly hindered by the steep expenses tied to creating, producing, and distributing these intricate biological treatments. Data from the Pharmaceutical Research and Manufacturers of America indicates that out of 52 new medicines approved in 2025, only six were novel vaccines and biologics. Additionally, the Biotechnology Innovation Organization highlighted in 2025 that financial backing for biotech startups dropped sharply from $2.6 billion in the first quarter to $900 million by the second quarter, emphasizing the tight financial conditions currently impacting the industry.

Market Driver

Progress in therapeutic technologies and biotechnology is significantly transforming the next-generation biotherapeutics industry by facilitating the creation of highly complex medical interventions. Breakthroughs in RNA-based treatments, cell therapy, and gene editing are broadening the range of conditions that can be treated while introducing innovative mechanisms of action. Consequently, an expanding portfolio of sophisticated biological treatments is successfully navigating the regulatory approval process. As noted by Contract Pharma on March 2, 2026, in its report "The 2026 Biologics Wave: Which Innovations Will Break Through?", the CDER had authorized 46 new drug therapies by the close of 2025, a dozen of which were biologics. This trend highlights the growing viability and advancement of next-generation biotherapeutics, which in turn draws more funding and skilled professionals to the field.

An additional major catalyst for this global market is the rising need for customized and highly targeted medical therapies, which signifies a major shift toward individualized patient healthcare. This surge in demand is driven by a more profound comprehension of disease variations and the capacity of these advanced therapies to deliver better results with fewer adverse effects than traditional options. These individualized strategies are especially crucial in challenging medical fields such as rare diseases and oncology. A MarketWatch report from March 27, 2026, titled "Personalized Medicine Market Share & Opportunities 2026-2033," predicts that North America will capture 44.4% of the personalized medicine sector in 2026, demonstrating strong regional uptake. Moreover, massive investments are flowing into the wider biopharmaceutical arena, with Fierce Biotech reporting in 2026 that major pharma corporations spent over $36 billion on biotech buyouts during just October and November of 2025, thereby sustaining the innovation and infrastructure needed to deliver these modern treatments worldwide.

Market Challenge

The immense financial requirements for researching, producing, and distributing next-generation biotherapeutics create a major hurdle for the growth of this market. Because these advanced treatments require in-depth scientific study, custom-built manufacturing centers, and rigorous regulatory compliance, the overall expenditures are exceptionally high. Consequently, this financial strain leads to exorbitant prices for the final therapies, which can restrict availability for a wider range of patients and ultimately hinder broader market acceptance and overall utilization.

Additionally, the massive financial investment necessary to advance these therapies presents a formidable obstacle for emerging biotech startups and smaller enterprises. Obtaining the requisite capital to support lengthy research phases and expansive production efforts proves difficult, especially when investors require rigorous proof of concept beforehand. Data from the Massachusetts Biotechnology Council shows that venture capital funding for companies based in Massachusetts reached $6.85 billion over 197 investment rounds in 2025. Although these figures indicate a recovery to numbers seen before the pandemic, they also highlight a fiercely competitive funding environment that can delay the journey of groundbreaking treatments from the laboratory to the commercial market.

Market Trends

Incorporating artificial intelligence into the creation of new medicines is drastically altering the global next-generation biotherapeutics sector by speeding up discovery and boosting research and development productivity. By moving past conventional lab techniques, this movement utilizes advanced computing to quickly pinpoint new drug targets, engineer better molecules, and forecast both safety and effectiveness. These AI applications are modernizing the initial phases of pharmaceutical development, fostering a more adaptable and data-centric approach. Illustrating the industry's strong confidence in this technological evolution, Eli Lilly and NVIDIA declared in January 2026 that they would co-invest up to $1 billion over a five-year period to establish an AI-driven laboratory dedicated to discovering novel drugs.

A parallel major trend is the rise of localized and point-of-care biological manufacturing systems, which play a vital role in effectively creating and supplying cutting-edge treatments, especially those tailored for rare conditions and personalized medicine. This transition circumvents the high costs and logistical difficulties of massive, centralized production by utilizing compact, adaptable facilities situated near patients or dedicated care facilities. Such frameworks capitalize on advancements like continuous manufacturing to lower the massive upfront investments typically needed to produce biologics. As highlighted by MedCity News on January 29, 2026, utilizing continuous manufacturing methods can shrink the required equipment space by as much as 70%, rendering these decentralized production networks much more cost-effective and functionally beneficial.

Key Market Players

  • Xencor, Inc.
  • Regenxbio & Neurimmune AG
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Kirin Co., Ltd
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Ono Pharmaceuticals Co, Ltd

Report Scope

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Biotherapeutics Market, By Therapeutic Area

  • Oncology
  • Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology

  • Antibody-Drug Conjugates
  • Bispecific Antibodies
  • Antibody Fragments
  • Antibody-like Proteins
  • Others

Next Generation Biotherapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next Generation Biotherapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases)
    • 5.2.2. By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Next Generation Biotherapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next Generation Biotherapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Next Generation Biotherapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Next Generation Biotherapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By Technology

7. Europe Next Generation Biotherapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next Generation Biotherapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By Technology
    • 7.3.2. France Next Generation Biotherapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Next Generation Biotherapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Next Generation Biotherapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Next Generation Biotherapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By Technology

8. Asia Pacific Next Generation Biotherapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Next Generation Biotherapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Next Generation Biotherapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Next Generation Biotherapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Next Generation Biotherapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Next Generation Biotherapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By Technology

9. Middle East & Africa Next Generation Biotherapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Next Generation Biotherapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By Technology
    • 9.3.2. UAE Next Generation Biotherapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By Technology
    • 9.3.3. South Africa Next Generation Biotherapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By Technology

10. South America Next Generation Biotherapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Next Generation Biotherapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By Technology
    • 10.3.2. Colombia Next Generation Biotherapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By Technology
    • 10.3.3. Argentina Next Generation Biotherapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Next Generation Biotherapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Xencor, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Regenxbio & Neurimmune AG
  • 15.3. Takeda Pharmaceutical Company Limited
  • 15.4. Pfizer, Inc.
  • 15.5. AstraZeneca Plc.
  • 15.6. F. Hoffmann-La Roche Ltd.
  • 15.7. Kyowa Kirin Co., Ltd
  • 15.8. Seattle Genetics, Inc
  • 15.9. ImmunoGen, Inc
  • 15.10. Ono Pharmaceuticals Co, Ltd

16. Strategic Recommendations

17. About Us & Disclaimer